Derivative exercise or conversion — not an open-market buy.
Traded Aug 6, 2026 · Filed Aug 7, 2026
Johnson & Johnson's Chief Legal Officer sold $2.41M of Johnson & Johnson shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$2,408,463
Shares × reported transaction price
22 days after results of Jul 15, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $256.98 on Aug 6, 2026, within 4% of its 52-week high, after a 7% rise over the previous 30 trading days
52-week range $171.53 (Aug 7, 2025) to $267.24 (Jul 7, 2026), 89% of the way up, from 251 adjusted closes. 30 trading days earlier: $241.00 on Jun 24, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Imaavy on Aug 24, 2026, 18 days after this trade.
New use approved (efficacy supplement). Active ingredient: Nipocalimab-Aahu. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.2% | -0.1% | +0.3% |
| 30 days | +2.0% | -1.4% | +3.4% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
37K → 25K shares held−30% of their stake
Johnson & Johnson's WW Chair, MedTech sold $3.04M of Johnson & Johnson shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.